Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | MMP16 | P51512 | 1/20 | 0.31 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446851 | 0.87 | CTSB (0.40) | CTSBALDH1A1HSD17B10TDP1PTGES2 | |
| SCHEMBL998791 | 0.80 | LIPG (0.41) | CTSBTDP1 | |
| SCHEMBL2818054 | 0.79 | LIPG (0.47) | — | |
| SCHEMBL1404117 | 0.77 | LIPG (0.50) | — | |
| SCHEMBL1404095 | 0.77 | LIPG (0.50) | — | |
| SCHEMBL11469686 | 0.77 | LIPG (0.50) | — | |
| SCHEMBL11361072 | 0.77 | LIPG (0.50) | — | |
| SCHEMBL1403964 | 0.77 | LIPG (0.50) | — | |
| SCHEMBL1403975 | 0.77 | LIPG (0.50) | — | |
| SCHEMBL1404140 | 0.77 | LIPG (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815829-B2 | 3′-azido purine nucleotide prodrugs for treatment of viral infections | RFS PHARMA, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120135951-A1 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-05-31 | — | — | US | disclosed |
| US-20100279969-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010068708-A2 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-2155771-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | RFS Pharma, LLC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008143846-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279969-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | CDA, APOBEC3G, DIMT1 | CTSB 2038/4885ALDH1A1 650/4885HSD17B10 2175/4885 |
| US-20120135951-A1 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | PNP, ENTPD5, ADA | CTSB 2370/4885ALDH1A1 912/4885HSD17B10 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.